Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARETHUSA Trial
2024-518526-33-01Phase 2Completed
- Sponsor
- IFOM
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in metastatic colon cancer (mCRC) (2 cohorts), sponsored by IFOM. Started Jan 2025; status: completed.
02
Drugs
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-518526-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518526-33-01.